profit from every $100 of sales.
$0$100
Satellos Bioscience
$6.95-7.21% today
+20.7% in 1 year
1-year low $5.591-year high $13.01
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Satellos Bioscience sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$24.9 million of profit last year.
SalesProfit
Satellos Bioscience vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Satellos Bioscience | No profit yet | ||
 Atai Beckley N.V | No profit yet | ||
 Avalyn Pharma | No profit yet | ||
 Cullinan Therapeutics | No profit yet | ||
 High Tide | No profit yet |
AI analysis
An AI analyst reads Satellos Bioscience's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -6 | -12 | -20 | -26 | |
| -8 | -12 | -20 | -26 | |
| -8 | -12 | -21 | -25 | |
| -2.83 | -1.63 | -2.16 | -1.70 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5 | 33 | 51 | 32 |
| Cash | 1 | 17 | 40 | 10 |
| Total debt | – | – | – | – |
| Total liabilities | 2 | 3 | 4 | 4 |
| 2 | 31 | 47 | 28 | |
| 3 | 7 | 10 | 15 | |
| -265.4% | -30.4% | -34.2% | -75.2% | |
| -336.1% | -38.9% | -43.7% | -89.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -4 | -9 | -18 | -24 | |
| 0 | 0 | 0 | 0 | |
| -4 | -9 | -18 | -24 | |
| Dividends paid | 0 | 0 | – | – |
| – | – | – | – | |
| 1 | 2 | 2 | 3 |
Valuation
- –
- –
- –
- 0.5×
- –
- –
- –
- -16.0%
- -16.9%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -20.7%
- -130.8%
- -51.4%
- -25.6%
- -20.7%
- –
Growth
- –
- –
- −35.6%
- –
- −11.8%
Financial health
- -2.7×
- 0.00
- 0.0%
- –
- 11.13
- 11.13
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 953
Bottom 21%of 877
Bottom 6%of 988
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.53 | -0.51 | −3.9% |
| Mar 27, 2026 | -0.47 | -0.36 | −30.6% |
| Nov 14, 2025 | -0.36 | -0.33 | −11.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
28No pass
Benjamin Graham
73Pass
Philip Fisher
42No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
39No pass
Terry Smith
39No pass
Questions about Satellos Bioscience
Is Satellos Bioscience a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Satellos Bioscience AI analysis
What does Satellos Bioscience do?
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It is in Medical - Pharmaceuticals.
Does Satellos Bioscience pay a dividend?
No. Satellos Bioscience does not pay a dividend at the moment.
Is Satellos Bioscience stock halal?
Yes. Satellos Bioscience passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Satellos Bioscience stock done over the past year?
Up 20.7% over the past twelve months, to $6.95. It traded between $5.59 and $13.01 and is 46.6% below its high.
Who are Satellos Bioscience's competitors?
The largest listed companies in the same industry are Atai Beckley N.V, Avalyn Pharma, Cullinan Therapeutics and High Tide. The peers table on this page compares their profit, growth and price with Satellos Bioscience's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.